GSK hepatitis B drug achieves functional cure in 1 in 5 patients

An experimental GSK drug achieved functional cure in approximately 20% of chronic hepatitis B patients in new clinical trial data, significantly outperforming existing treatments. The results represent a potential breakthrough in treating chronic hepatitis B, which affects millions globally and can lead to liver cirrhosis and cancer. For Medicaid managed care organizations, improved hepatitis B treatments could reduce long-term pharmacy costs and downstream complications requiring expensive specialty care, particularly relevant given Medicaid's high enrollment of populations at elevated risk for chronic hepatitis B.

Pharmacy · Managed Care